Canaccord Genuity reaffirms Buy rating on Apogee Therapeutics stock after positive trial data

3 days ago 2
Read Entire Article
  1. Homepage
  2. Finance
  3. Canaccord Genuity reaffirms Buy rating on Apogee Therapeutics stock after positive trial data

Related

Marc Benioff says AI is radically reshaping Salesforce, and 51% of Q1 hiring was internal as thousands of employees were redeployed

Marc Benioff says AI is radically reshaping Salesforce, and ...

15 minutes ago 0
Jefferies lists out key points after Bilibili's investor day

Jefferies lists out key points after Bilibili's investor day...

16 minutes ago 0
Kraft Heinz considering split to unlock value - Wall Street Journal

Kraft Heinz considering split to unlock value - Wall Street ...

19 minutes ago 0
Nutrien downgraded at Jefferies, seeing more risks on the horizon

Nutrien downgraded at Jefferies, seeing more risks on the ho...

21 minutes ago 0
Starbucks is in the spotlight as the hunt for a partner in China continues

Starbucks is in the spotlight as the hunt for a partner in C...

30 minutes ago 0
Brookdale director slate elected amid proxy fight with Ortelius

Brookdale director slate elected amid proxy fight with Ortel...

48 minutes ago 0
Quant check for consumer staple stocks before Q2 earnings

Quant check for consumer staple stocks before Q2 earnings

53 minutes ago 0
U.S. budget balance unexpectedly flips to surplus in June

U.S. budget balance unexpectedly flips to surplus in June

53 minutes ago 0
Exclusive: Crypto and stablecoin infrastructure startup zerohash to raise $100 million at almost $1 billion valuation

Exclusive: Crypto and stablecoin infrastructure startup zero...

55 minutes ago 0
Senator Blumenthal voices concern over JetBlue, United's Blue Sky partnership

Senator Blumenthal voices concern over JetBlue, United's Blu...

59 minutes ago 0
Novartis loses patent challenge to block MSN Pharma’s generic Entresto

Novartis loses patent challenge to block MSN Pharma’s generi...

1 hour ago 0
Wall Street sees 35% Canada tariff as just a negotiation tactic: ‘Tariffs are Trump’s hammer for every nail’

Wall Street sees 35% Canada tariff as just a negotiation tac...

1 hour ago 0
Tech Voices: Intel's robotics spinout, Goldman's AI coder, Tesla

Tech Voices: Intel's robotics spinout, Goldman's AI coder, T...

1 hour ago 0
Freeport-McMoRan downgraded at UBS after popping from copper tariffs

Freeport-McMoRan downgraded at UBS after popping from copper...

1 hour ago 0
Levi Strauss' Q2 results should 'relieve investor doubts' -- analysts

Levi Strauss' Q2 results should 'relieve investor doubts' --...

1 hour ago 0
SA analyst upgrades/downgrades: CVX, TLRY, LULU, REGN

SA analyst upgrades/downgrades: CVX, TLRY, LULU, REGN

1 hour ago 0
15 breakout winners in 2025’s worst-performing S&P sector

15 breakout winners in 2025’s worst-performing S&P sector

1 hour ago 0
The Rise of the Everyday Millionaire, or the EMILLI

The Rise of the Everyday Millionaire, or the EMILLI

2 hours ago 0
Franklin Street Properties declares $0.01 dividend

Franklin Street Properties declares $0.01 dividend

2 hours ago 0
Casino stocks trade lower after state gaming revenue reports disappoint

Casino stocks trade lower after state gaming revenue reports...

2 hours ago 0

Trending

1. airpods
2. athenea del castillo
3. amazon prime
4. rbi notification 2025
5. s24 ultra
6. psg vs chelsea
7. jeļena ostapenko
8. youtube monetization update
9. portugal vs belgium
10. italy vs spain

Popular

TechCrunch Mobility: The state of EV sales and Rivian secures the next $1B from VW

TechCrunch Mobility: The state of EV sales and Rivian secure...

1 week ago 8
Castelion raises $350M Series B to scale hypersonic missile business

Castelion raises $350M Series B to scale hypersonic missile ...

1 week ago 6
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© FBT Company 2025. All rights are reserved